- Brand Name : Portrazza
- Drug Class : How Do Antineoplastic EGFR Inhibitors Work?
- Medical Author : John P. Cunha, DO, FACOEP
- Medical Reviewer :
- _eael_post_view_count : 7
What Is Necitumumab Used For and How Does it Work?
Necitumumab is used for first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin.
Necitumumab is available under the following different brand names: Portrazza.
What Are the Dosages of Necitumumab?
Dosages of Necitumumab:
Dosage Forms and Strengths
Intravenous (IV) solution
- 800 mg/50mL (16mg/mL)
Dosage Considerations – Should be Given as Follows:
Non-small Cell Lung Cancer
- Indicated for first-line treatment of metastatic squamous NSCLC in combination with gemcitabine and cisplatin
- 800 mg intravenously (IV) infused over 1 hour on days 1 and 8 of each 3-week cycle before gemcitabine and cisplatin infusion
- Continue therapy until disease progression or unacceptable toxicity
Dosage Modifications
Infusion-related reactions
- Grade 1: Reduce the infusion rate by 50%
- Grade 2: Stop the infusion until signs and symptoms have resolved to grade 0 or 1; resume infusion at 50% reduced rate for all subsequent infusions
- Grade 3 or 4 IRR: Permanently discontinue
- Also, see Administration
Dermatologic toxicity
- Grade 3 rash or acneiform rash: Withhold until symptoms resolve to grade up to 2, then resume infusion at a reduced dose of 400 mg for at least 1 treatment cycle; if symptoms do not worsen, may increase the dose to 600 mg and 800 mg in subsequent cycles
- Permanently discontinue if:
- Grade 3 rash or acneiform rash do not resolve to grade up to 2 within 6 weeks
- Reactions worsen or become intolerable at a dose of 400 mg
- Patient experiences grade 3 skin induration/fibrosis
- Grade 4 dermatologic toxicity
Dosing Considerations
- Limitations of use: Not indicated for the treatment of non-squamous NSCLC
- Safety and efficacy not established in pediatric patients